TransCode Therapeutics Surges on New Cancer Nanotechnology Publication
Sep 23, 2021 By MarketDepth
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. “The imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode’s TTX platform for delivery of RNA targeted therapy to metastatic solid tumors,” according to the company’s press release.
Up 26% Premarket
TransCode Therapeutics stock gained over 26% in premarket trading.
Results as Intended
The key results of the study showed that TTX-MC138 accumulated in metastatic lesions once after being injected intravenously, with the results of the study suggesting that the platform delivers its therapeutic candidate as intended.
“Our TTX technology builds upon prior experience with similar iron oxide nanoparticles that have long been used in humans for imaging, potentially enabling clinical studies that may de-risk future clinical trials by demonstrating successful drug delivery and assist in patient selection for future treatment.”
Michael Dudley, CEO of TransCode Therapeutics
